NASDAQ:AKBA - Akebia Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $10.29
  • Forecasted Upside: 196.42 %
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.47
▼ -0.81 (-18.93%)
1 month | 3 months | 12 months
Get New Akebia Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKBA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKBA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$10.29
▲ +196.42% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $10.29, with a high forecast of $18.00 and a low forecast of $3.00. The average price target represents a 196.42% upside from the last price of $3.47.
Hold
The current consensus among 7 polled investment analysts is to hold stock in Akebia Therapeutics. This rating has held steady since April 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/5/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/4/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
i
10/26/2020HC WainwrightLower Price TargetBuy$10.00 ➝ $9.00High
i
9/4/2020Morgan StanleyLower Price TargetEqual Weight$12.00 ➝ $3.00High
i
9/4/2020BTIG ResearchLower Price TargetBuy$26.00 ➝ $6.00Medium
i
9/4/2020HC WainwrightLower Price TargetBuy$17.00 ➝ $10.00Medium
i
9/4/2020MizuhoLower Price TargetBuy$17.00 ➝ $6.00Medium
i
9/3/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
i
8/11/2020Needham & Company LLCInitiated CoverageBuy$18.00High
i
Rating by Chad Messer at Needham & Company LLC
8/11/2020MizuhoReiterated RatingBuy$17.00High
i
7/15/2020Morgan StanleyBoost Price TargetEqual Weight$11.00 ➝ $12.00Medium
i
7/15/2020HC WainwrightReiterated RatingBuyHigh
i
6/29/2020Needham & Company LLCInitiated CoverageBuy$18.00High
i
Rating by Chad Messer at Needham & Company LLC
5/6/2020Royal Bank of CanadaBoost Price TargetPositive ➝ Sector Perform$8.00 ➝ $12.00Low
i
5/6/2020Morgan StanleyBoost Price TargetEqual Weight$9.00 ➝ $11.00Low
i
5/6/2020JPMorgan Chase & Co.Boost Price TargetOverweight$13.00 ➝ $18.00Low
i
5/6/2020MizuhoBoost Price TargetBuy$15.00 ➝ $17.00Medium
i
5/6/2020HC WainwrightBoost Price TargetBuy$16.00 ➝ $17.00Medium
i
5/5/2020Needham & Company LLCBoost Price TargetBuy$15.00 ➝ $18.00High
i
Rating by Chad Messer at Needham & Company LLC
3/19/2020MizuhoReiterated RatingBuy$15.00High
i
3/11/2020MizuhoLower Price TargetBuy$16.00 ➝ $15.00High
i
3/10/2020Needham & Company LLCReiterated RatingBuy$15.00High
i
2/20/2020JPMorgan Chase & Co.Boost Price TargetOverweight$10.00 ➝ $13.00High
i
2/19/2020HC WainwrightReiterated RatingBuy$16.00High
i
11/19/2019MizuhoReiterated RatingBuy$16.00Medium
i
Rating by Difei Yang at Mizuho
11/14/2019Needham & Company LLCLower Price TargetBuy$18.00 ➝ $15.00Medium
i
9/9/2019HC WainwrightReiterated RatingBuy$17.00High
i
8/9/2019MizuhoSet Price TargetBuy$16.00N/A
i
Rating by Difei Yang at Mizuho
8/6/2019HC WainwrightLower Price TargetBuy ➝ Buy$19.00 ➝ $17.00High
i
7/11/2019HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $21.00Medium
i
5/2/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$12.00High
i
3/20/2019CitigroupInitiated CoverageNeutral ➝ Neutral$9.00High
i
12/4/2018MizuhoReiterated RatingBuy$17.00Medium
i
9/7/2018Morgan StanleyInitiated CoverageEqual ➝ Equal WeightHigh
i
Rating by David Lebovitz at Morgan Stanley
9/7/2018Morgan StanleySet Price TargetEqual Weight ➝ Hold$9.00Low
i
8/13/2018Raymond JamesInitiated CoverageBuy$18.00Medium
i
8/10/2018Needham & Company LLCLower Price TargetBuy$20.00 ➝ $18.00Medium
i
8/9/2018Royal Bank of CanadaReiterated RatingHold$13.00Medium
i
6/29/2018HC WainwrightReiterated RatingBuyHigh
i
6/6/2018HC WainwrightLower Price TargetBuy$24.00 ➝ $22.00High
i
5/10/2018MizuhoReiterated RatingBuy$24.00Low
i
Rating by Salim Syed at Mizuho
3/13/2018MizuhoReiterated RatingBuy$24.00High
i
Rating by Salim Syed at Mizuho
3/7/2018MizuhoSet Price TargetBuy$24.00High
i
Rating by Salim Syed at Mizuho
2/13/2018MizuhoReiterated RatingBuy$24.00Low
i
12/18/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$26.00Medium
i
12/7/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$30.00Medium
i
11/15/2017HC WainwrightReiterated RatingBuy$24.00N/A
i
Rating by E. Arce at HC Wainwright
11/9/2017MizuhoReiterated RatingBuy$24.00N/A
i
11/2/2017Royal Bank of CanadaReiterated RatingHold$17.00N/A
i
10/4/2017MizuhoInitiated CoverageBuy$24.00N/A
i
9/16/2017Royal Bank of CanadaReiterated RatingOutperform$28.00Low
i
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$17.00High
i
8/9/2017HC WainwrightReiterated RatingBuy$24.00High
i
7/10/2017HC WainwrightLower Price TargetBuy ➝ Buy$25.00 ➝ $24.00Medium
i
6/30/2017AegisReiterated RatingBuyHigh
i
6/6/2017HC WainwrightReiterated RatingBuy$25.00Medium
i
6/5/2017AegisReiterated RatingBuyMedium
i
5/18/2017AegisReiterated RatingBuy$25.00Low
i
5/17/2017Needham & Company LLCReiterated RatingBuy$18.00 ➝ $21.00Low
i
Rating by Chad Messer at Needham & Company LLC
5/17/2017HC WainwrightReiterated RatingNeutral$21.00 ➝ $25.00Low
i
5/5/2017UBS GroupReiterated RatingBuy$12.00 ➝ $17.00N/A
i
4/28/2017AegisBoost Price TargetBuy$21.00 ➝ $25.00Low
i
4/27/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$14.00 ➝ $18.00High
i
Rating by Chad Messer at Needham & Company LLC
4/27/2017HC WainwrightBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.00High
i
4/26/2017JMP SecuritiesBoost Price TargetOutperform$19.00 ➝ $21.00High
i
3/24/2017AegisReiterated RatingBuyLow
i
2/14/2017AegisReiterated RatingBuy$21.00N/A
i
12/27/2016HC WainwrightBoost Price TargetBuy$17.00 ➝ $18.00N/A
i
12/20/2016Needham & Company LLCSet Price TargetBuy$14.00N/A
i
Rating by Chad Messer at Needham & Company LLC
12/20/2016JMP SecuritiesBoost Price TargetOutperform$16.00 ➝ $19.00N/A
i
11/15/2016AegisInitiated CoverageBuy$18.00N/A
i
11/10/2016JMP SecuritiesReiterated RatingBuyN/A
i
9/29/2016Brean CapitalInitiated CoverageBuy$18.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
8/23/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Ed Arce at HC Wainwright
8/11/2016JMP SecuritiesReiterated RatingMarket Perform$16.00N/A
i
8/9/2016Credit Suisse GroupReiterated RatingHold$8.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
8/9/2016UBS GroupSet Price TargetBuy$12.00N/A
i
Rating by Jeffrey Hung at UBS Group AG
7/12/2016Credit Suisse GroupReiterated RatingHoldN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/16/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Ed Arce at HC Wainwright
5/8/2016UBS GroupReiterated RatingBuy$16.00 ➝ $12.00N/A
i
Rating by Jeffrey Hung at UBS Group AG
5/8/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Jonathan Aschoff at Brean Capital
5/8/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by Andrew Berens at Morgan Stanley
3/16/2016Brean CapitalInitiated CoverageBuyN/A
i
Rating by Jonathan Aschoff at Brean Capital
3/16/2016Needham & Company LLCLower Price TargetBuy$18.00 ➝ $14.00N/A
i
Rating by Chad Messer at Needham & Company LLC
3/16/2016HC WainwrightLower Price TargetBuy$25.00 ➝ $18.00N/A
i
Rating by Ed Arce at HC Wainwright
3/10/2016HC WainwrightLower Price TargetBuy$25.00 ➝ $18.00N/A
i
Rating by Ed Arce at HC Wainwright
3/10/2016Brean CapitalInitiated CoverageBuy$26.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$24.00 ➝ $16.00N/A
i
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$24.00 ➝ $16.00N/A
i
(Data available from 2/26/2016 forward)
Akebia Therapeutics logo
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $3.47
$3.42
$3.85

50 Day Range

MA: $3.78
$3.04
$5.06

52 Week Range

Now: $3.47
$2.09
$13.71

Volume

15,005,769 shs

Average Volume

7,674,686 shs

Market Capitalization

$501.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Akebia Therapeutics?

The following Wall Street analysts have issued research reports on Akebia Therapeutics in the last twelve months: BTIG Research, HC Wainwright, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for AKBA.

What is the current price target for Akebia Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Akebia Therapeutics in the last year. Their average twelve-month price target is $10.29, suggesting a possible upside of 196.4%. JPMorgan Chase & Co. has the highest price target set, predicting AKBA will reach $18.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $3.00 for Akebia Therapeutics in the next year.
View the latest price targets for AKBA.

What is the current consensus analyst rating for Akebia Therapeutics?

Akebia Therapeutics currently has 1 sell rating, 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AKBA, but not buy more shares or sell existing shares.
View the latest ratings for AKBA.

What other companies compete with Akebia Therapeutics?

How do I contact Akebia Therapeutics' investor relations team?

Akebia Therapeutics' physical mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is 617-871-2098 and its investor relations email address is [email protected] The official website for Akebia Therapeutics is www.akebia.com.